• Praxis Precision Medicines recently presented at Guggenheim Securities’ Emerging Outlook: Biotech Summit 2026 and scheduled its fourth-quarter and full-year 2025 results and corporate update for February 19, 2026, highlighting upcoming regulatory milestones for ulixacaltamide and relutrigine, both with FDA Breakthrough Therapy Designation and planned New Drug Application submissions by mid-February.
• What stands out is how tightly the company’s investor outreach, conference appearances and impending dual NDA filings are aligning to spotlight a potential shift in its late-stage pipeline toward commercial readiness.
• We’ll now examine how the imminent dual NDA submissions, combined with intensified investor outreach, influence Praxis Precision Medicines’ existing investment narrative.

Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.

Praxis Precision Medicines Investment Narrative Recap

To own Praxis today, you have to believe that ulixacaltamide and relutrigine can convert FDA Breakthrough Therapy Designations and imminent NDAs into real commercial products while the broader epilepsy pipeline matures. The near term upside catalyst is the dual NDA submissions by mid February, which could clarify regulatory timelines. The biggest current risk is that Praxis remains loss making as it spends heavily on late stage programs, and this news does not materially change that funding and execution risk.

The most relevant update here is Guggenheim’s increased US$800 price target, tied to ulixacaltamide’s essential tremor opportunity and the expected mid February NDA filing. This bullish stance sits alongside other positive rating changes and an average Street target that implies meaningful upside, amplifying how much weight the market is putting on successful approval and launch. Against that backdrop, the February 19 earnings and corporate update may reset how investors view both cash needs and execution timelines.

Yet behind the enthusiasm, investors should be aware that heavy cash burn, recent dilution and concentrated late stage risk could still...

Praxis Precision Medicines' narrative projects $724.1 million revenue and $89.5 million earnings by 2029. This requires 359.5% yearly revenue growth and a $362.5 million earnings increase from $-273.0 million today.

Uncover how Praxis Precision Medicines' forecasts yield a $449.13 fair value, a 39% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were assuming revenue of about US$76.6 million by 2028 and still no clear profitability, which is far more cautious than the narrative built around breakthrough designations and a funded runway, reminding you that views on Praxis can differ sharply and may shift again as the new NDA news is fully absorbed.

Explore 4 other fair value estimates on Praxis Precision Medicines - why the stock might be worth less than half the current price!

Build Your Own Praxis Precision Medicines Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Praxis Precision Medicines research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Praxis Precision Medicines research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Praxis Precision Medicines' overall financial health at a glance.

Contemplating Other Strategies?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.